FOI_6878

Internal Reference Number: FOI_6878

Date Request Received: 21/11/2022 00:00:00

Date Request Replied To: 22/11/2022 00:00:00

This response was sent via: By Email

Request Summary: Pre-eclampsia treatment

Request Category: Companies


Question Number 1: Pre-eclampsia is a condition affecting up to one in ten pregnancies, and can lead to serious complications for both mother and baby if not monitored and treated. In cases of pre-eclampsia, levels of cental growth factor (PlGF) in the blood can be abnormally low and a sign that the placenta is not developing properly. 1.Is your trust currently implementing PIGF-based testing to diagnose pre-eclampsia?

Answer To Question 1: No

Question Number 2: If so, how many tests has your trust implemented each year over the past 5 calendar years (2018, 2019, 2020, 2021, 2022 YTD)

Answer To Question 2: n/a

Question Number 3: If not, please outline the reasons why your trust is not currently implementing PIGF-based testing. Please answer with reference to the fact that PIGF-based testing has been recommended by National Institute of Health and Care Excellence (NICE) to both rule in and rule out pre-eclampsia for people presenting with suspected symptoms.

Answer To Question 3: Pilot was instigated for 12 months, low uptake in tests due to population therefore trust did not pursue this test.

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.